ESPE Abstracts

Background: Gonadotropin-releasing hormone agonists (GnRHa) have been widely used to treat patients with central precocious puberty (CPP). Several studies have investigated changes in body composition in patients with CPP following GnRHa treatment. But the results are inconsistent. This study aimed to investigate the influence of GnRHa treatment on the weight and body mass index (BMI) of girls who were diagnosed with idiopathic CPP or early puberty (EP).

Methods: Patients who were younger than 8 years of age at diagnosis were classified as CPP and patients aged between 8 and 9 years at diagnosis were classified as EP. Of 89 patients 22 were diagnosed with CPP and 67 were diagnosed with EP. The patients were treated with triptorelin for 1 year. Changes in weight and body mass index were monitored prospectively. The patients were grouped according to pretreatment weight status into normal weight, overweight, and obesity.

Results: Significant changes were observed with respect to weight standard deviation score (SDS) and BMI SDS after 6 months and 1 year of treatment, respectively. Depending on the degree of obesity, normal weight group showed significant increments of BMI SDS.

Conclusion: Weight SDS and BMI SDS increased in triptorelin acetate treated patients significantly as a whole group. BMI SDS increased significantly in the normal weight group after 6 months and 1 year of triptorelin treatment.